BLAINJECTIONINJECTABLE
Approved
Jul 2015
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
23
Data completeness
4/8 — Partial
PRALUENT (alirocumab) by Regeneron is pcsk9 inhibitors [moa]. Approved for pcsk9 inhibitor [epc]. First approved in 2015.
Drug data last refreshed 20h ago
Mechanism of Action
PCSK9 Inhibitors
Pharmacologic Class:
PCSK9 Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (23)
A Real-World Study of Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and Alirocumab
Started Apr 2026
5,995 enrolled
Cardiovascular DiseasesAtherosclerotic Cardiovascular DiseaseHypercholesterolemia, Familial
A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia
Started Apr 2026
420 enrolled
Hypercholesterolemia
Alirocumab in Patients with Sepsis
Started Jan 2023
50 enrolled
Sepsis
Non-interventional Study on the Monthly Administration of 300 mg AliRocumab (PRALUENT®) With the 2 ml SYDNEY Auto-injector
Started Nov 2021
163 enrolled
Primary Hypercholesterolaemia and Mixed DyslipidaemiaAtherosclerotic Cardiovascular Disease
Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients
Started Apr 2021
204 enrolled
HypercholesterolemiaCardiovascular Diseases
Worked on PRALUENT at Regeneron? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.